HC Wainwright Rates BioCryst Pharmaceuticals (BCRX) buy

Analyst Andrew S. Fein keeps a bullish stance with a $32 price target, contrasting with more modest forecasts across the street, a 220% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 11:02 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated BioCryst Pharmaceuticals, Inc. ($BCRX) "buy" with a $32 price target on June 30, 2026.

Since the rating, $BCRX is up 9.9% after 1 week, down 7.6% after 1 month and down 22.1% to date (from the $10 close on Jun 30, 2026).

BCRX BioCryst Pharmaceuticals, Inc.

$7.79 +3.87% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating and $32.00 price target on BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX) on June 30, 2026.
HC Wainwright's $32 price target implies 220% upside from BioCryst Pharmaceuticals, Inc.'s ($BCRX) current $10 share price.
The stock trades around $10.00, sitting well above its 52-week low of $6.00 and near its high of $11.22.
Wall Street holds a consensus buy recommendation with a mean price target of $20.64 across 11 analyst opinions.

Get $BCRX trade alerts by text

We text you when insiders, Congress or big funds trade $BCRX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BioCryst Pharmaceuticals, Inc. alert may contain errors. Disclosures

HC Wainwright Keeps Its High Hopes for BioCryst

HC Wainwright analyst Andrew S. Fein kept a buy rating and a $32.00 price target on BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX) on June 30, 2026. That target sits well above where the stock trades today, making it one of the more optimistic calls on the street for the rare disease drug maker.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +62.39% hypothetical

All-time return +170.34% S&P 500 +28.65%

vs. S&P 500 +141.69% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

How This Call Compares With Wall Street

While HC Wainwright points toward $32.00, other major firms take a more cautious approach. On September 30, 2026, JP Morgan maintained a neutral rating with a $13.00 price target, up from its prior $12.00 goal. Earlier in the month on September 10, 2026, RBC Capital downgraded the stock to sector perform and trimmed its target to $11.00 from $13.00. Needham kept a buy rating with a $16.00 target on September 8, 2026. Back on August 6, 2026, Wedbush kept an outperform rating with a $20.00 target. Cantor Fitzgerald also maintained an overweight rating with a $29.00 target on June 30, 2026. Overall, the company carries a consensus buy recommendation from 11 analysts with a mean target of $20.64, spanning from a low of $11.00 to that high of $32.00.

BioCryst Stock Moves Past Its 50-Day Average

Shares of BioCryst change hands around $10.00 on Tuesday, trading inside a 52-week window that stretches from a low of $6.00 to a high of $11.22. The price rests above its 50-day moving average of $9.40 and its 200-day moving average of $8.65. The company carries a market value of about $2.24 billion and trades at a forward P/E ratio of 9.32.

12-month forecast

$BCRX price target

BioCryst Pharmaceuticals, Inc. daily closes and this analyst's $32 target. Not advice.

What BioCryst Pharmaceuticals Does

BioCryst Pharmaceuticals, Inc. is a biotech firm headquartered in Durham, North Carolina. It focuses on discovering, developing, and selling medicines for rare conditions like hereditary angioedema. Its treatments include the oral therapy Orladeyo and the influenza treatment Rapivab, alongside a clinical pipeline targeting other immune and rare disease indications.

Looking Ahead to November Earnings

The company is scheduled to release its next financial results on November 2, 2026. Investors will look to see how key product sales and pipeline updates progress as the year wraps up.